Drug Profile
Research programme: Id protein modulators - AngioGenex
Alternative Names: AGX 1053; AGX 8Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer AngioGenex
- Class Antisense DNA; Peptides; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Inhibitor of differentiation protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Eye disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA
- 16 Apr 2019 This programme is still in active development